# OncoC4

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncoc4

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.oncoc4.com/
- Total disclosed funding: $50M
- Latest round: Series B (Oct 2, 2025)
- Investors on record: 4

## About

OncoC4, Inc., based in the US, is focused on developing innovative therapies for challenging cancers and Alzheimer's disease, utilizing cutting-edge immune checkpoint approaches.Founded in 2020 and headquartered in Rockville, US, OncoC4, Inc. specializes in oncology solutions. The company has raised a total of USD 50.00 mn through three investment rounds, with the latest being a Series B round led by GBA Fund, also involving 3E Bioventures Capital, HM Capital, and Kaitai Capital.OncoC4 specializes in developing next-generation therapies targeting hard-to-treat cancers and Alzheimer’s disease. Their primary offerings include pioneering treatments that leverage innate and adaptive immune checkpoints, specifically focusing on CTLA-4, CD24, and Siglec signaling pathways. These therapeutics aim to enhance immune response against cancer cells while minimizing adverse effects associated with traditional therapies. Their portfolio encompasses monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and CAR T-cell therapies. OncoC4's products are designed for use in clinical settings, primarily targeting healthcare institutions and specialists involved in oncology and immunotherapy. The company serves markets across North America, Europe, and Asia, collaborating with various healthcare partners and research institutions to advance treatment options for patients with advanced malignancies.OncoC4 generates revenue through partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers. Their business model is primarily B2B, focusing on strategic alliances for clinical development and commercialization of their innovative therapies. Revenue streams include milestone payments, licensing agreements, and royalties derived from product sales. The company’s flagship products, such as their PD-1/VEGF bispecific program and CTLA-4 antibody therapies, are central to their revenue generation, as they are positioned to disrupt existing treatment paradigms for immunotherapy-resistant cancers. These offerings are expected to facilitate a range of transactions that ensure continuous funding for further research and development, solidifying OncoC4’s position in the oncology market.OncoC4, Inc. plans to expand its product offerings, focusing on new therapies aimed at enhancing treatment efficacy for oncology and Alzheimer's disease. The upcoming products are targeted for launch within the next 18 months. The company also aims to penetrate additional markets in Asia and Europe by 2025, leveraging its recent funding of USD 50.00 mn to support these initiatives and enhance its research and development capabilities.

## Funding rounds

- Series B, Oct 2, 2025, $50M — Kaitai Capital, 3E Bioventures Capital, HM Capital, Greater Bay Area Homeland Investments

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series B
- Greater Bay Area Homeland Investments — Series B